Globus Medical price target lowered to $75 from $82 at Barclays

Barclays analyst Matt Miksic lowered the firm’s price target on Globus Medical (GMED) to $75 from $82 and keeps an Overweight rating on the shares. While the merger with NuVasive (NUVA) remains the central topic of discussion, Globus Medical’s Q4 earnings results beat Street expectations on sales inline with the pre-release, the analyst tells investors in a research note. The firm believes risks around the merger are more than adequately discounted at current share levels. It notes that Globus remains committed to the NuVasive deal, seeing compelling synergies in operations and sales.